Long-Term Heart Rate Reduction Induced by the Selective If Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure

Circulation

Volumn 109, Issue 13, 2004, Pages 1674-1679

  Mulder, Paul ^a   Barbier, Stephane ^a   Chagraoui, Abdeslam ^a   Richard, Vincent ^a   Henry, Jean Paul ^a   Lallemand, Françoise ^a   Renet, Sylvanie ^a   Lerebours, Guy ^b   Mahlberg Gaudin, Florence ^b   Thuillez, Christian ^a  

^a INSERM   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Drugs; Heart failure; Heart rate; Pathology

Indexed keywords

COLLAGEN; IVABRADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GEOMETRY; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE CAPILLARY; HEART MUSCLE CELL; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART WEIGHT; ISOLATED HEART; MALE; NONHUMAN; OXYGEN SUPPLY; PATHOLOGY; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; RAT; SINUS NODE;

ANIMALS; BENZAZEPINES; CAPILLARIES; CARDIAC OUTPUT; COLLAGEN; DRUG EVALUATION, PRECLINICAL; HEART FAILURE, CONGESTIVE; HEART RATE; HEART VENTRICLES; ION TRANSPORT; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, WISTAR; SINOATRIAL NODE; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 11144356194     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000118464.48959.1C     Document Type: Article

References (32)

1. Spinale FG, Zellner JL, Tomita M, et al. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res. 1991;69:1058-1067.
2. Spinale FG, Tomita M, Zellner JL, et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991;261:H308-H318.
3. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428-1433.
4. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441-1446.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
6. Nagatsu M, Spinale FG, Koide M, et al. Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. Circulation. 2000;101:653-659.
7. Brown MD, Hudlicka O. Protective effects of long-term bradycardial pacing against catecholamine-induced myocardial damage in rabbit hearts. Circ Res. 1988;62:965-974.
8. Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994;112:37-42.
9. Gardiner SM, Kemp PA, March JE, et al. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol. 1995;115:579-586.
10. Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659-666.
11. Monnet X, Ghaleh B, Colin P, et al. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther. 2001;299:1133-1139.
12. Bois P, Bescond J, Renaudon B, et al. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118:1051-1057.
13. Pfeffer MA, Pfeffer JM, Steinberg C, et al. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985;72:406-412.
14. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976-1982.
15. Derumeaux G, Mulder P, Richard V, et al. Tissue Doppler imaging differentiates physiological from pathological pressure-overload left ventricular hypertrophy in rats. Circulation. 2002;105:1602-1608.
16. Contard F, Glukhova M, Sabri A, et al. Comparative effects of indapamide and hydrochlorothiazide on cardiac hypertrophy and vascular smooth-muscle phenotype in the stroke-prone, spontaneously hypertensive rat. J Cardiovasc Pharmacol. 1993;22(suppl 6):S29-S34.
17. Mulder P, Devaux B, Richard V, et al. Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure: effects on survival, hemodynamics, and cardiovascular remodeling. Circulation. 1997;95:1314-1319.
18. Litwin SE, Litwin CM, Raya TE, et al. Contractility and stiffness of noninfarcted myocardium after coronary ligation in rats: effects of chronic angiotensin converting enzyme inhibition. Circulation. 1991;83:1028-1037.
19. Raya TE, Gay RG, Lancaster L, et al. Serial changes in left ventricular relaxation and chamber stiffness after large myocardial infarction in rats. Circulation. 1988;77:1424-1431.
20. Litwin SE, Katz SE, Morgan JP, et al. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994;89:345-354.
21. Shinke T, Takeuchi M, Takaoka H, et al. Beneficial effects of heart rate reduction on cardiac mechanics and energetics in patients with left ventricular dysfunction. Jpn Circ J. 1999;63:957-964.
22. Ryu KH, Tanaka N, Ross J Jr. Effects of a sinus node inhibitor on the normal and failing rabbit heart. Basic Res Cardiol. 1996;91:131-139.
23. Anversa P, Beghi C, Kikkawa Y, et al. Myocardial response to infarction in the rat: morphometric measurement of infarct size and myocyte cellular hypertrophy. Am J Pathol. 1985;118:484-492.
24. Zheng W, Brown MD, Brock TA, et al. Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor. Circ Res. 1999;85:192-198.
25. Boudoulas H, Rittgers SE, Lewis RP, et al. Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion. Circulation. 1979;60:164-169.
26. Guth BD, Heusch G, Seitelberger R, et al. Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis. Circulation. 1987;75:661-669.
27. Nadaud S, Philippe M, Arnal JF, et al. Sustained increase in aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high blood flow. Circ Res. 1996;79:857-863.
28. Varin R, Mulder P, Richard V, et al. Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure: role of nitric oxide, prostanoids, and oxidant stress. Circulation. 1999;99:2951-2957.
29. Kapadia SR. Cytokines and heart failure. Cardiol Rev. 1999;7:196-206.
30. Ide T, Tsutsui H, Kinugawa S, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res. 2000;86:152-157.
31. Luyt CE, Lepailleur-Enouf D, Gaultier CJ, et al. Involvement of the endothelin system in experimental critical hind limb ischemia. Mol Med. 2000;6:947-956.
32. Kjekshus J. Heart rate reduction: a mechanism of benefit? Eur Heart J. 1987;8(suppl L):115-122.